In the realm of medical research, the focus on vaginal and vulvar cancers has often been overshadowed by more prevalent diseases. However, a recent study by Ambika Aul, Professor Susan Jordan, and Dr. Tracey DiSipio sheds light on the critical need for improved guidelines and awareness in the diagnosis and prevention of these rare but significant cancers. The study, which conducted a systematic review of existing guidelines, highlights several key areas where progress is needed, particularly in incorporating consumer views and enhancing the applicability of recommendations.
One of the most striking findings of the study is the stark contrast in survival rates between vaginal and vulvar cancers and more common women's cancers like breast and endometrial cancers. While the five-year relative survival rates for vaginal and vulvar cancers are 53% and 74%, respectively, these figures drop significantly to 93% and 84% for breast and endometrial cancers. This disparity underscores the urgent need for tailored guidelines and increased awareness among healthcare professionals.
The rarity of vaginal and vulvar cancers poses a unique challenge. In 2025, only 117 new cases of vaginal cancers and 401 new cases of vulvar cancers were diagnosed in Australia. This scarcity means that general practitioners are less likely to encounter these cancers during their careers, leading to a lack of familiarity with their diagnosis and management. The study emphasizes the importance of additional education and guidance for clinicians to improve clinical assessment and, consequently, prevention and diagnosis.
The guidelines reviewed by the authors identified consistent recommendations for prevention and early detection. The HPV vaccination is highlighted as a crucial tool in preventing precursor conditions such as vaginal intraepithelial neoplasia (VIN) and, by extension, vaginal and vulvar cancer. Opportunistic screening through cervical screening offers the opportunity to diagnose these cancers and their precursors through visual examination. Biopsy is warranted if lesions do not resolve or are suspected to be invasive.
However, the study also points out several gaps in the current guidelines. Few guidelines incorporate the views and preferences of consumers, which is crucial for ensuring the guidelines' applicability across a range of settings. The authors argue that including consumers from identified priority groups during the development of Optimal Care Pathways (OCPs) can help address known inequities. Priority population groups, as identified by The Australian Cancer Plan, include Aboriginal and Torres Strait Islander people, people living in rural and remote areas, and older Australians.
Furthermore, the guidelines were rated low in terms of applicability. To improve this, the authors suggest that guidelines should address facilitators and barriers to implementing the recommendations, provide advice on how to put the recommendations into practice, describe the potential resource implications, and outline methods for monitoring guideline uptake. The creation of an OCP for vaginal and vulvar cancers in Australia could help improve current practices by combining existing evidence and expert opinion presented in guidelines.
The study also highlights the importance of evaluating current screening practices before creating new OCPs. The National Cervical Screening Program offers the opportunity to detect cancers and their precursors through visual examination of the vulva and vagina. While self-collection for HPV screening is effective in reaching under- and never-screened women, it limits opportunities for incidental findings during physical exams. The impact of self-collection on HPV-independent cases should be considered.
In conclusion, the study by Aul, Jordan, and DiSipio underscores the critical need for improved guidelines and awareness in the diagnosis and prevention of vaginal and vulvar cancers. By addressing the gaps in current guidelines and incorporating consumer views, healthcare professionals can better support patients and improve outcomes for those affected by these rare but significant cancers.
